Nasus Pharma announced positive interim results from its Phase 2 clinical study of NS002, an investigational intranasal epinephrine powder formulation for anaphylaxis treatment. Results show NS002 achieved faster absorption and higher peak concentrations compared to EpiPen®. 91% of participants reached the 100 pg/ml plasma threshold at 5 minutes with NS002, compared to 67% with EpiPen®. NS002 was well-tolerated with no serious adverse events reported. Full Phase 2 results are expected by the end of the first quarter of 2026, with a pivotal study planned for the fourth quarter of 2026.

Read more at GlobeNewswire: Nasus Pharma Announces Positive Interim Results from Phase